(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) in the last 10 years. While the most commonly utilized approaches in prostate cancer are cytotoxic chemotherapy or target the androgen-axis, recently, theranostic treatment with 177Lu-PNT2002 (also known as [Lu-177]-PSMA-I&T) has demonstrated promising activity among pre-treated individuals with mCRPC. To date, 177Lu-PNT2002 has been administered to more than 300 patients in administrative reports with PSA responses of 50% or greater in 38-59% of patients.